The present disclosure relates to high-throughput screening methods for identifying one or more chromatography operational parameters (e.g., binding parameters) and/or reagents for purifying EVs (e.g., exosomes) from a sample using chromatography. Also disclosed herein are methods for improving one or more aspects of EV (e.g., exosome) purification, e.g., improving EV yield, increasing EV ligand density, and/or reducing impurity recovery.

A method for rapid detection of dry eye syndrome includes collecting a first tear fluid from healthy participant and a second tear fluid from patient with eye dryness; isolating EV samples from the first tear fluid; acquiring a first fingerprint diagram of proteomes of the EV samples from the first tear fluid, the first fingerprint diagram comprises a plurality of first discriminant peaks; isolating EV samples from the second tear fluid; acquiring a second fingerprint diagram of proteomes of the EV samples from the second tear fluid, the second fingerprint diagram comprises a plurality of second discriminant peaks; and comparing the first discriminant peaks and the second discriminant peaks to determine whether the patient has the DES. This is a fast and precise method for detecting the DES of the participant.

The subject of the invention is the method of detecting and diagnosing the progression of diabetes using Raman spectroscopy which involves the examination of the changes in the composition of urinary extracellular vesicles which confirm the existence of the condition and its progression. The invention can be applied in clinical practice, in particular in the early clinical diagnostics of diabetes and in the monitoring of its progression, in particular diabetic nephropathy and advanced renal impairment caused by diabetes.

The current disclosure provides for novel therapeutic methods by identifying patient populations that may be treated effectively by immunotherapies. It was found that responders of immunotherapeutic treatments have a higher amount of B-cell exosomes in their blood than non-responders. Aspects of the disclosure relate to a method of treating cancer in a subject comprising administering to the subject immune checkpoint blockade (ICB) therapy after B-cell exosomes have been detected in a biological sample from the subject.

A first buffer fluid containing a first bead having fixed to a surface thereof a first antibody that specifically binds to a first antigen is injected into a reaction container, and then a plurality of a second bead having fixed to a surface thereof a second antibody that specifically binds to an optional second antigen, and a biological sample containing an exosome to be analyzed having the first antigen and the second antigen on a surface of the exosome are injected into the reaction container, thereby generating a second buffer fluid. An exosome having the first bead and the second bead bound thereto is collected from the second buffer fluid. The exosome having the first bead and the second bead bound thereto is separated into the first bead, the second bead, and the exosome, and the second bead and the exosome are individually collected.

The present invention provides a method of measuring the quality of therapeutic cells through real-time glutathione monitoring.

The invention relates to the technical field of medicine, and provides a method of screening and identifying small molecule with anti-aging properties. The method comprises cellular models, namely premature aging mouse embryonic fibroblasts and human HGPS mesenchymal stem cells and animal models, namely premature aging progeroid mice and Caenorhabditis elegans. The method successfully screened and identified Cannabidiol (CBD), which had senolytic effects. The invention also determined that the optimal concentration of CBD treatment is 10-20 μM.

The present invention relates to a marker that can be used as aging biomarker. More specifically, the present invention relates to the analysis of nucleolar size as a biomarker for aging and metabolic health and its relation to the virtual age, or the life expectancy of animals, including humans. The aging biomarker of the invention can be used to study the effect of medication, food compounds and/or special diets on the wellness and virtual age, or the life expectancy of animals, including humans.

The present invention addresses a problem of providing a method for collecting extracellular vesicles derived from nervous system cells at an improved efficiency.

This problem is solved by a method for collecting extracellular vesicles derived from nervous system cells, said method comprising a step for mixing an anti-APLP1 antibody with a sample containing extracellular vesicles to form anti-APLP1 antibody-extracellular vesicle complexes and a step for collecting the anti-APLP1 antibody-extracellular vesicle complexes.

The present invention provides recovering an extracellular vesicle(s) having high purity from an extracellular vesicle-containing sample. Specifically, the present invention provides a method of recovering an extracellular vesicle(s), comprising: (1) treating an extracellular vesicle-containing sample with a chelating agent; and (2) separating the extracellular vesicle(s) from the extracellular vesicle-containing sample treated with the chelating agent.